ClinicalTrials.gg
CompletedNCT01412060Updated Jul 6, 2018Results posted

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

A Phase 3 interventional study of Placebo and Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 73 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-07-06.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
765
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
Largest of 23
765 · median 129
Started
2011
with 1 other
Phase 3
8 of 23
1 open now
Registered
9th of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one has the largest enrollment, is one of 2 that started in 2011, is one of 8 in phase 3, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.

Read the detailed description

There were 3 periods (phases) in the study. The Open-label Phase lasted 20 weeks. In the first 6 weeks, participants received 3, 6, or 9 mg cariprazine orally once a day; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this Open-label Phase. At the end of Week 8, participants had to meet the following criteria to continue in the study.

  • Positive and Negative Syndrome Scale (PANSS) total score ≤ 60 at the end of Week 8
  • At least 20% decrease in PANSS total score from baseline to the end of Week 8
  • Clinical Global Impressions - Severity (CGI-S) score ≤ 4 at the end of Week 8
  • Score of ≤ 4 on each of the following 7 PANSS items: P1, P2, P3, P6, P7, G8, and G14 at the end of Week 8
  • Stable dose during the previous 2 weeks
  • No significant tolerability issues as judged by the Investigator at the end of Week 8

At the end of the Open-label Phase, participants were randomized into 2 treatment groups, cariprazine or placebo, if they met the following criteria:

  • PANSS total score ≤ 60 at the end of Week 20
  • At least 20% decrease in PANSS total score from baseline to the end of Week 20
  • CGI-S score ≤ 4 at the end of Week 20
  • Score of ≤ 4 on each of the following 7 PANSS items: P1, P2, P3, P6, P7, G8, and G14 at the end of Week 20
  • No significant tolerability issues as judged by the Investigator During this Double-blind Treatment Phase, participants received either placebo or cariprazine at the same dosage (3, 6, or 9 mg) that they received during the last 14 weeks of the Open-label Phase.

All participants entered the 4 week Safety Follow-up Phase. They received a treatment other than the investigational product at the discretion of the Investigator.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Schizophrenic disorder
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have provided prior to any study specific procedures.
  • Participants currently meeting the , Fourth Edition - Text Revision (DSM-IV-TR) criteria for schizophrenia.
  • Participants with normal physical examination, laboratory, vital signs, and/or (ECG).
  • Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).
  • Positive and Negative Syndrome Scale (PANSS) total score ≥ to 70 and ≤ 120 at Visit 1 (Screening) and Visit 2 (beginning of Run-in Phase).
  • Negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test (applies to female participants of only).
  • between 18 and 40 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Participants currently meeting criteria for schizoaffective disorder, schizophreniform disorder, bipolar I and II and known or suspected borderline or antisocial personality disorder. or other DSM-IV-TR axis II disorders.
  • Participants in their first episode of psychosis.
  • Treatment-resistant schizophrenia over the last 2 years.
  • Positive result from the blood alcohol test or from the urine drug screen for any prohibited medication.
  • At imminent risk of injuring self or others or causing significant damage to property.
  • Suicide risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
765 participants (actual)

Study arms

  • Experimental
    Cariprazine - Open-label Phase

    Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.

    Drug: Cariprazine

  • Experimental
    Placebo - Double-blind Treatment Phase

    Participants received placebo orally once a day for 26 to 72 weeks.

    Drug: Placebo

  • Experimental
    Cariprazine - Double-blind Treatment Phase

    Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks

    Drug: Cariprazine

Interventions

  • DrugPlacebo

    Placebo was supplied in capsules.

  • Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.

    Also known as: RGH-188

06

What researchers measure

Primary outcomes

  1. Time From Baseline to the First Symptom Relapse During the Double-blind Phase

    Relapse was defined as meeting ≥1 of the following criteria:1-Hospitalization due to worsening of condition;2-increase in Positive and Negative Syndrome Scale(PANSS) total score by ≥30% for participants,scored ≥50 or a ≥10-point increase for participants,scored \<50 at randomization;3-increase in Clinical Global Impressions-Severity(CGI-S) score by ≥2 points at Week 20;4-deliberate self-injury or aggressive behaviour;5-suicidal/homicidal ideation judged clinically significant by Investigator;6-score of \>4 on 1 or more of following PANSS items:P1,P2,P3,P6,P7,G8 or G14. Second assessment not performed based on Investigator discretion. PANSS is 30-item rating scale. Each item scored on 7-point scale. Total score ranges from 30 to 210. Lower score indicates fewer schizophrenic symptoms. CGI-S is 7-point scale,measures severity of participant's illness in comparison with others with same diagnosis. Lower score indicates less severe illness. 25th percentile for time to relapse was reported.

    Time frame: Up to 34 Weeks and Bi-Weekly thereafter until Week 92

07

Results

Posted Jul 6, 2018

Participant flow

Open-label Run-in Period (RIP)
Participant flow — Open-label Run-in Period (RIP)
MilestoneCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment Phase
Started76500
Completed41800
Not completed34700
Withdrew: Adverse event8600
Withdrew: Insufficient therapeutic response6600
Withdrew: Protocol violation2700
Withdrew: Withdrawal of consent11700
Withdrew: Lost to follow-up3200
Withdrew: Other miscellaneous reasons1900
Period Between RIP and SP
Participant flow — Period Between RIP and SP
MilestoneCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment Phase
Started41800
Completed36400
Not completed5400
Withdrew: Adverse event400
Withdrew: Insufficient therapeutic response1900
Withdrew: Protocol violation200
Withdrew: Withdrawal of consent100
Withdrew: Lost to follow-up500
Withdrew: Other miscellaneous reasons2300
Open-label Stabilization Period (SP)
Participant flow — Open-label Stabilization Period (SP)
MilestoneCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment Phase
Started36400
Completed26400
Not completed10000
Withdrew: Adverse event900
Withdrew: Insufficient therapeutic response900
Withdrew: Protocol violation1400
Withdrew: Withdrawal of consent4000
Withdrew: Lost to follow-up900
Withdrew: Other miscellaneous reasons1900
Period Between SP and DBP
Participant flow — Period Between SP and DBP
MilestoneCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment Phase
Started26400
Completed20000
Not completed6400
Withdrew: Protocol violation200
Withdrew: Withdrawal of consent200
Withdrew: Lost to follow-up100
Withdrew: Did not met criteria to enter next phase400
Withdrew: Other miscellaneous reasons5500
Double-blind Treatment Phase (DBP)
Participant flow — Double-blind Treatment Phase (DBP)
MilestoneCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment Phase
Started099101
Completed01618
Not completed08383
Withdrew: Adverse event056
Withdrew: Protocol violation045
Withdrew: Withdrawal of consent01015
Withdrew: Lost to follow-up065
Withdrew: Other miscellaneous reasons01127
Withdrew: Relapse04725

Outcome measures

PrimaryTime From Baseline to the First Symptom Relapse During the Double-blind Phase

Relapse was defined as meeting ≥1 of the following criteria:1-Hospitalization due to worsening of condition;2-increase in Positive and Negative Syndrome Scale(PANSS) total score by ≥30% for participants,scored ≥50 or a ≥10-point increase for participants,scored \<50 at randomization;3-increase in Clinical Global Impressions-Severity(CGI-S) score by ≥2 points at Week 20;4-deliberate self-injury or aggressive behaviour;5-suicidal/homicidal ideation judged clinically significant by Investigator;6-score of \>4 on 1 or more of following PANSS items:P1,P2,P3,P6,P7,G8 or G14. Second assessment not performed based on Investigator discretion. PANSS is 30-item rating scale. Each item scored on 7-point scale. Total score ranges from 30 to 210. Lower score indicates fewer schizophrenic symptoms. CGI-S is 7-point scale,measures severity of participant's illness in comparison with others with same diagnosis. Lower score indicates less severe illness. 25th percentile for time to relapse was reported.

Time frame:
Up to 34 Weeks and Bi-Weekly thereafter until Week 92
Reported as:
Number · Days
Time From Baseline to the First Symptom Relapse During the Double-blind Phase
DaysPlaceboCariprazine
Time From Baseline to the First Symptom Relapse During the Double-blind Phase92 (44 to 151)224 (99 to NA)
Statistical analysis
  • Placebo vs Cariprazine · Log Rank · p = 0.0010 · Hazard ratio (hr): 0.45 · 95% CI 0.28 to 0.73Hazard ratio (cariprazine 3-9 mg vs placebo) is based on Cox proportional hazards regression model, with treatment group as an explanatory variable.

Adverse events

Collected over First dose until 30 days after last dose of investigational product [Open-Label (Up to 184 days) and Double-Blind (Up to 536 days)]. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine - Open-label Phase0/765 (0%)50/765 (6.5%)425/765 (55.6%)
Placebo - Double-blind Treatment Phase0/99 (0%)14/99 (14.1%)28/99 (28.3%)
Cariprazine - Double-blind Treatment Phase0/101 (0%)14/101 (13.9%)35/101 (34.7%)
Open-label - Safety Follow-up Phase0/765 (0%)6/765 (0.8%)0/765 (0%)
Placebo - Safety Follow-up Phase0/99 (0%)2/99 (2%)0/99 (0%)
Cariprazine - Safety Follow-up Phase0/101 (0%)0/101 (0%)0/101 (0%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment PhaseOpen-label - Safety Follow-up PhasePlacebo - Safety Follow-up PhaseCariprazine - Safety Follow-up Phase
SchizophreniaPsychiatric disorders19/7657/995/1013/7650/990/101
Psychotic disorderPsychiatric disorders10/7652/992/1013/7651/990/101
Schizophrenia, paranoid typePsychiatric disorders3/7650/992/1010/7650/990/101
Atrial fibrillationCardiac disorders0/7651/990/1010/7650/990/101
Cholecystitis acuteHepatobiliary disorders0/7651/990/1010/7650/990/101
Generalised tonic-clonic seizureNervous system disorders0/7651/990/1010/7650/990/101
Ischaemic strokeNervous system disorders0/7651/990/1010/7650/990/101
Middle ear effusionEar and labyrinth disorders0/7651/990/1010/7650/990/101
Otitis media acuteInfections and infestations0/7651/990/1010/7650/990/101
Sinus tachycardiaCardiac disorders0/7651/990/1010/7650/990/101
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCariprazine - Open-label PhasePlacebo - Double-blind Treatment PhaseCariprazine - Double-blind Treatment PhaseOpen-label - Safety Follow-up PhasePlacebo - Safety Follow-up PhaseCariprazine - Safety Follow-up Phase
AkathisiaNervous system disorders148/7650/990/1010/7650/990/101
InsomniaPsychiatric disorders110/7658/998/1010/7650/990/101
HeadacheNervous system disorders92/7657/998/1010/7650/990/101
RestlessnessPsychiatric disorders70/7650/990/1010/7650/990/101
NasopharyngitisInfections and infestations0/7655/998/1010/7650/990/101
TremorNervous system disorders0/7650/998/1010/7650/990/101
Extrapyramidal disorderNervous system disorders55/7653/996/1010/7650/990/101
Weight increasedInvestigations49/7650/990/1010/7650/990/101
NauseaGastrointestinal disorders48/7650/990/1010/7650/990/101
SchizophreniaPsychiatric disorders0/7656/994/1010/7650/990/101

Baseline characteristics

Run-in Phase safety population: All participants who received at least 1 dose of open-label cariprazine during the Run-in Phase of the study.

Age, Continuous
Age, Continuous(years)Cariprazine - Open-label Phase
Mean38.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine - Open-label Phase
Female221
Male544
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cariprazine - Open-label Phase
Hispanic or Latino37
Not Hispanic or Latino728
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cariprazine - Open-label Phase
American Indian or Alaska Native0
Asian149
Native Hawaiian or Other Pacific Islander1
Black or African American313
White299
More than one race3
Unknown or Not Reported0
Weight
Weight(kg)Cariprazine - Open-label Phase
Mean78.07 ± 20.10
Height
Height(cm)Cariprazine - Open-label Phase
Mean170.98 ± 9.95
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cariprazine - Open-label Phase
Mean26.50 ± 5.63
Waist circumference
Waist circumference(cm)Cariprazine - Open-label Phase
Mean90.39 ± 15.34
08

Study locations

73 sites
  • Forest Investigative Site 011
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 018
    Cerritos, California 90703, United States
  • Forest Investigative Site 007
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 026
    Culver City, California 90230, United States
  • Forest Investigative Site 008
    Long Beach, California 90813, United States
  • Forest Investigative Site 002
    Oceanside, California 92056, United States
  • Forest Investigative Site 019
    Orange, California 92868, United States
  • Forest Investigative Site 001
    Paramount, California 90723, United States
  • Forest Investigative Site 020
    San Diego, California 92123, United States
  • Forest Investigative Site 005
    Washington, District of Columbia 20016, United States
  • Forest Investigative Site 024
    Leesburg, Florida 34748, United States
  • Forest Investigative Site 017
    Atlanta, Georgia 30331, United States
  • Forest Investigative Site 021
    Chicago, Illinois 60640, United States
  • Forest Investigative Site 023
    Baltimore, Maryland 21202, United States
  • Forest Investigative Site 010
    Rockville, Maryland 20850, United States
  • Forest Investigative Site 003
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site 006
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 014
    Saint Louis, Missouri 63141, United States
  • Forest Investigative Site 012
    Cedarhurst, New York 11516, United States
  • Forest Investigative Site 022
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 015
    Austin, Texas 78731, United States
  • Forest Investigative Site 027
    Austin, Texas 78754, United States
  • Forest Investigative Site 025
    Dallas, Texas 75231, United States
  • Forest Investigative Site 013
    Houston, Texas 77008, United States
  • Forest Investigative Site 009
    Houston, Texas 77021, United States
  • Forest Investigative Site 305
    Vijayawada, Andhra Pradesh 520002, India
  • Forest Investigative Site 303
    Ahmedabad, Gujarat 380006, India
  • Forest Investigative Site 308
    Ahmedabad, Gujarat 380006, India
  • Forest Investigative Site 310
    Ahmedabad, Gujarat 380015, India
  • Forest Investigative Site 313
    Mangalore, Karnataka 575018, India
  • Forest Investigative Site 314
    Manipal, Karnataka 576104, India
  • Forest Investigative Site 301
    Aurangabad, Maharashtra 431005, India
  • Forest Investigative Site 306
    Kalyan, Maharashtra 421301, India
  • Forest Investigative Site 311
    Nashik, Maharashtra 422101, India
  • Forest Investigative Site 317
    Jaipur, Rajasthan 302021, India
  • Forest Investigative Site 302
    Jaipur, Rajasthan 303706, India
  • Forest Investigative Site 312
    Madurai, Tamilnadu 625020, India
  • Forest Investigative Site 309
    Kanpur, Uttar Pradesh 208005, India
  • Forest Investigative Site 304
    Lucknow, Uttar Pradesh 226003, India
  • Forest Investigative Site 307
    Varanasi, Uttar Pradesh 221005, India
  • Forest Investigative Site 403
    Bucuresti, 041914, Romania
  • Forest Investigative Site 405
    Bucuresti, 041914, Romania
  • Forest Investigative Site 406
    Bucuresti, 041914, Romania
  • Forest Investigative Site 408
    Bucuresti, 041914, Romania
  • Forest Investigative Site 410
    Bucuresti, 041914, Romania
  • Forest Investigative Site 407
    Campulung, 115100, Romania
  • Forest Investigative Site 412
    Campulung, 115100, Romania
  • Forest Investigative Site 402
    Constanta, 900002, Romania
  • Forest Investigative Site 411
    Focsani, 620165, Romania
  • Forest Investigative Site 401
    Iasi, 700282, Romania
  • Forest Investigative Site 409
    Iasi, 700282, Romania
  • Forest Investigative Site 404
    Targoviste, 130086, Romania
  • Forest Investigative Site 508
    Bratislava, 81369, Slovakia
  • Forest Investigative Site 507
    Bratislava, 82606, Slovakia
  • Forest Investigative Site 504
    Liptovsky Mikulas, 03125, Slovakia
  • Forest Investigative Site 505
    Rimavska Sobota, 97912, Slovakia
  • Forest Investigative Site 503
    Roznava, 04801, Slovakia
  • Forest Investigative Site 506
    Trnava, 91701, Slovakia
  • Forest Investigative Site 609
    Kerch, AR Crimea 98310, Ukraine
  • Forest Investigative Site 610
    Dnipropetrovsk, 49115, Ukraine
  • Forest Investigative Site 613
    Donetsk, 83008, Ukraine
  • Forest Investigative Site 616
    Ivano-Frankivsk, 76014, Ukraine
  • Forest Investigative Site 605
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 606
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 604
    Kharkiv, 61103, Ukraine
  • Forest Investigative Site 607
    Kherson, 73488, Ukraine
  • Forest Investigative Site 602
    Kyiv, 02660, Ukraine
  • Forest Investigative Site 601
    Kyiv, 04080, Ukraine
  • Forest Investigative Site 612
    Kyiv, 04080, Ukraine
  • Forest Investigative Site 603
    Lviv, 79021, Ukraine
  • Forest Investigative Site 615
    Odesa, 65014, Ukraine
  • Forest Investigative Site 611
    Simferopol, 95006, Ukraine
  • Forest Investigative Site 608
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Correll CU, Potkin SG, Zhong Y, Harsanyi J, Szatmari B, Earley W. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. J Clin Psychiatry. 2019 Jan 8;80(2):18m12495. doi: 10.4088/JCP.18m12495. PubMed 30695290 ↗
  • Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016 Oct;176(2-3):264-271. doi: 10.1016/j.schres.2016.06.030. Epub 2016 Jul 15. Erratum In: Schizophr Res. 2018 Feb;192:493. doi: 10.1016/j.schres.2017.04.020. PubMed 27427558 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Sep 2014, 35 months.

Results were first posted in Jul 2018, 3 years 10 months after primary completion. A results delay was requested in Sep 2015.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 35 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2011
First posted
Aug 8, 2011
StartActual
Sep 27, 2011
Primary completionActual
Sep 3, 2014
CompletionActual
Sep 3, 2014
Results delay requested
Sep 25, 2015
Results first posted
Jul 6, 2018
Last update
Jul 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01412060
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Aug 8, 2011
Start date
Sep 27, 2011
Primary completion
Sep 3, 2014
Completion
Sep 3, 2014
Results posted
Jul 6, 2018
Last update
Jul 6, 2018

Study contacts

Willie Earley
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion